Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779039 | 0.83 | ALDH1A1 (0.46) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL5754563 | 0.82 | CYP2D6 (0.40) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL5495026 | 0.77 | ATM (0.55) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL24302110 | 0.76 | CYP2D6 (0.43) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL1492823 | 0.76 | CYP2D6 (0.43) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL12847815 | 0.75 | EBP (0.37) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL21858220 | 0.75 | TAAR1 (0.54) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL7886997 | 0.75 | ESR1 (0.46) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL27486307 | 0.75 | CYP2D6 (0.42) | CYP2D6DRD2DRD4OPRM1DRD3 | |
| SCHEMBL25463733 | 0.74 | ALDH1A1 (0.37) | CYP2D6DRD2DRD4OPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776965-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-03 | — | — | US | disclosed |
| US-20160168094-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-16 | — | — | US | disclosed |
| US-9302987-B2 | Pyrrolidinyl derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-04-05 | — | — | US | disclosed |
| EP-2456309-B1 | Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV. | GLAXOSMITHKLINE LLC (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2456309-B1 | Azabicyclo[3.2.1]octyl derivatives for use in the treatment of HIV. | GLAXOSMITHKLINE LLC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150183735-A1 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-02 | — | — | US | disclosed |
| US-9012494-B2 | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-04-21 | — | — | US | disclosed |
| EP-1747199-B1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| US-8592395-B2 | Therapeutic compounds | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120295877-A1 | Therapeutic Compounds | GLAXOSMITHKLINE LLC | 2012-11-22 | — | — | US | disclosed |
| WO-2011011652-A1 | THERAPEUTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-27 | — | — | WO | disclosed |
| CN-101001836-B | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV | 2010-12-22 | — | — | CN | disclosed |
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20080139625-A1 | Metabolic syndrome; compounds are 1,3-substituted-2-oxo-(pyrrolidines or piperidines); 3-[(2,6-Dichlorophenyl)methyl]-1-(1-phenylpropyl)-2-pyrrolidinone for example | INSTITUTE OF ORGANIC CHEMISTRY, BULGARIAN ACADEMY OF SCIENCES (BG) | 2008-06-12 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
| CN-101001836-A | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-18 | — | — | CN | disclosed |
| EP-1747199-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005108360-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295877-A1 | Therapeutic Compounds | CCR5, CCR1, CXCR3 | CYP2D6 1811/4885DRD2 2856/4885DRD4 2708/4885 |
| US-20150183735-A1 | PYRROLIDINYL DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | CYP2D6 251/4885DRD2 461/4885DRD4 838/4885 |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | CYP2D6 218/4885DRD2 228/4885DRD4 442/4885 |
| US-20160168094-A1 | PYRROLIDIN-2-ONE AND PIPERIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | HSD3B1, HSDL2, HSD11B1 | CYP2D6 325/4885DRD2 412/4885DRD4 949/4885 |
| US-20080139625-A1 | Metabolic syndrome; compounds are 1,3-substituted-2-oxo-(pyrrolidines or piperidines); 3-[(2,6-Dichlorophenyl)methyl]-1-(1-phenylpropyl)-2-pyrrolidinone for example | NAT1, CBR1, PC | CYP2D6 504/4885DRD2 1345/4885DRD4 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.